Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of trends in single inhaler triple therapy (SITT) use and clinical characteristics of patients with severe asthma: data from the IRSA registry.

European annals of allergy and clinical immunology·2025
Same author

The added value of targeting airway hyperresponsiveness by blocking thymic stromal lymphopoietin (TSLP) in the management of severe asthma.

European annals of allergy and clinical immunology·2024
Same author

Cascade of care for TB infection in persons newly diagnosed with HIV in Italy.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2024
Same author

Chronic rhinosinusitis with nasal polyposis and biological agents: the ARIA-ITALY survey.

European annals of allergy and clinical immunology·2024
Same author

Severe asthma: follow-up after one year from the Italian Registry on Severe Asthma (IRSA)

European annals of allergy and clinical immunology·2023
Same author

Severe Asthma and Biologics: Managing Complex Patients.

Journal of investigational allergology & clinical immunology·2022
Same journal

Methotrexate and folic acid supplementation in rheumatoid arthritis: A Japanese claims database and 538,985 patients from April 2015 to November 2020.

International journal of clinical pharmacology and therapeutics·2026
Same journal

Cardiac arrest in an adolescent following an overdose of antidepressants comprising sertraline, quetiapine fumarate, and lamotrigine: Case report.

International journal of clinical pharmacology and therapeutics·2026
Same journal

Recombinant human growth hormone in pediatric patients using the FAERS database: Safety profile and update for the period 2004 - 2024.

International journal of clinical pharmacology and therapeutics·2026
Same journal

The triple neuromodulatory-immunomodulatory axis.

International journal of clinical pharmacology and therapeutics·2026
Same journal

Novel intravenous human IVIG in patients with secondary immunodeficiency: Interim analysis of a multicenter, prospective, non-interventional study.

International journal of clinical pharmacology and therapeutics·2026
Same journal

Network meta-analysis of bisphosphonates in the treatment of bone metastases from breast cancer.

International journal of clinical pharmacology and therapeutics·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats
05:55

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Published on: September 27, 2024

Erdosteine affects eicosanoid production in COPD.

R W Dal Negro1, M Visconti, S Tognella

  • 1Lung Department, Orlandi General Hospital, Bussolengo, Verona, Italy. rdalnegro@ulss22.ven.it

International Journal of Clinical Pharmacology and Therapeutics
|December 24, 2010
PubMed
Summary
This summary is machine-generated.

Erdosteine significantly reduced inflammatory eicosanoids and blood reactive oxygen species (ROS) in COPD patients. This study confirms erdosteine

Related Experiment Videos

Last Updated: Jun 5, 2026

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats
05:55

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Published on: September 27, 2024

Area of Science:

  • Biochemistry
  • Pharmacology
  • Respiratory Medicine

Background:

  • Oxidant-antioxidant imbalance and lipid peroxidation activate the 5-LO pathway, increasing inflammatory eicosanoids.
  • Erdosteine exhibits antioxidant properties, reducing 8-isoprostane in COPD patients.

Purpose of the Study:

  • To assess erdosteine's effects on eicosanoids.
  • To compare the time-course of erdosteine's effects with its antioxidant activity.

Main Methods:

  • 12 moderate COPD patients received erdosteine (300 mg b.i.d.) or placebo for 10 days.
  • Blood ROS, serum LTB4, and urine LTE4 were measured at baseline and on days 1, 3, 5, and 10.
  • Analysis of covariance (ANCOVA) was performed.

Main Results:

  • Erdosteine significantly decreased serum LTB4 and urine LTE4 levels (p < 0.001).
  • A significant reduction in blood ROS was observed in the erdosteine group.
  • FEV1 showed a significant increase in the erdosteine group compared to placebo (p = 0.0088).

Conclusions:

  • Erdosteine's scavenging and anti-inflammatory effects were confirmed.
  • Erdosteine significantly impacts eicosanoids, highlighting its anti-inflammatory potential in COPD.
  • Further research is needed to evaluate erdosteine's role in managing chronic respiratory inflammation.